<DOC>
	<DOC>NCT02590939</DOC>
	<brief_summary>The main objective of this study is to assess the efficacy of the Cefaly® device as an acute treatment of migraine attack in adult patients. The patients will be applied either an active or placebo external neurostimulation for 1 hour during a migraine attack, and will report the pain on a visual analog scale before and after the treatment.</brief_summary>
	<brief_title>Randomized Controlled Trial on Acute Treatment of Migraine With the Cefaly® Device</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>History of episodic or chronic migraine with or without aura meeting the diagnostic criteria listed in ICHDIII beta (2013) section 1, migraine, with the exception of ''complicated migraine'' (i.e., hemiplegic migraine, basilartype migraine, ophthalmoplegic migraine, migrainous infarction) Having a migraine attack lasting at least 3 hours Migraine pain intensity stabilized for at least 1 hour Frontal, retro, or peri orbital headache. Pregnant women Patients having received Botox treatment in the prior 4 months Patients having received supraorbital nerve blocks in the prior 4 months Diagnosis of other primary or secondary headache disorders, except of Medication Overuse Headache Patients with only temporal or occipital headache Patients using opioid medication Patients having taken abortive migraine medication in the prior 3 hours Allodynia: intolerance to supraorbital neurostimulation (allodynia) that makes the treatment not applicable (the patients will be excluded if they are unable to tolerate the first 5 minutes of neurostimulation). Implanted metal or electrical devices in the head Cardiac pacemaker or implanted or wearable defibrillator Patient having had a previous experience with Cefaly®</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>